2026, Pharmaceuticals, Small Molecule and Virus

The challenges and trends of cell & gene therapies

Drug Discovery World

SEPTEMBER 6, 2022

As is always the case with pharmaceuticals, the industry’s capabilities to manufacture and produce these potentially life-saving therapies will be of concern. . In gene therapy, re-engineered adeno-associated virus (AAV) vectors have been produced using various methods such as machine learning or directed evolution. Manufacturing

Therapies

Therapies Clinical Trials Vaccine Disease

Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.

The Pharma Data

JANUARY 6, 2021

Beyond fiscal year ending March 2026 , Fujifilm expects this latest investment to boost the annual growth rate of its Bio CDMO Business to 20%, greatly exceeding market projections. Going forward, Fujifilm will continue to contribute to the healthcare industry by providing a stable supply of high quality pharmaceuticals. *

Packaging

Packaging Small Molecule Production FDA Approval

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Pfizer announced several key advances in its efforts to protect humankind from the COVID-19 pandemic and prepare the pharmaceutical industry to better respond to future global health crises.

Vaccine

Vaccine Therapies Trials Clinical Trials

Drug Discovery Digest

The challenges and trends of cell & gene therapies

Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

Stay Connected